In conclusion, our novel cancer vaccination therapy comprising two peptides that bind multi-HLAs with Poly-ICLC and hLAG-3Ig adjuvants achieved highly effective induction of antigen-specific CTLs in patients with metastatic GI cancers. The gene discussed is HLA-S; the disease is cancer.